MRL Ventures Fund
Venture capitalCambridge · Seed–Series A · 3 people tracked
Investment thesis
MRL Ventures Fund is the early-stage corporate venture arm of Merck & Co., Inc., investing in therapeutic companies from its Cambridge, Massachusetts office. The fund targets innovative life sciences ventures globally across the therapeutics sector.
Team · 3 people
from the firm's websiteFrequently asked questions
- What stage does MRL Ventures Fund invest at?
- MRL Ventures Fund invests at the Seed, Series A stages.
- What is MRL Ventures Fund's typical check size?
- MRL Ventures Fund typically writes checks of $25M.
- What sectors does MRL Ventures Fund focus on?
- MRL Ventures Fund focuses on Biotech, Medical Devices.
- Where is MRL Ventures Fund located?
- MRL Ventures Fund is headquartered in Cambridge, US.
Similar investors
ACT Venture Capital is an independent Irish venture capital firm that invests €1 million to €15 million in growth-stage private companies, with capacity for larger commitments through syndicated rounds.
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
Breyer Capital is a venture capital firm that invests in high-impact entrepreneurs with a strategic focus on companies leveraging artificial intelligence and machine learning to transform technology sectors globally.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.